YMAB (ymabs.com) קצב צמיחת רווח למניה בשנה הנוכחית

Y-mAbs Therapeutics (YMAB) is retaining key researchers while simultaneously recruiting global distribution experts. Growth is driven by the success of Danyelza, the GD2-SADA platform, and new patents. However, geopolitical tensions are hindering drug exports and international trials. The YoY earnings per share (EPS) trend reflects market expectations, with the metric standing at 9.90, which helps assess earnings adaptability.

For the biotech sector, where Y-mAbs Therapeutics (YMAB) is implementing innovative radioimmunotherapy for cancer, this indicator serves as a measure of efficiency in transitioning from antibody development to monetization. By analyzing the relative annual growth of net income per share, an investor can see the percentage change in EPS compared to the previous period, allowing for an assessment of the business's actual profitability through the lens of real profit extraction.